Previously, transfection of EGFR siRNA into metastatic prostate cancer cells resulted in decreased intracellular glucose levels, whereas treatment with an EGFR kinase inhibitor did not affect intracellular glucose.[16]. The gene discussed is EGFR; the disease is Familial prostate cancer.